Results 91 to 100 of about 1,343 (178)

A method of comprehensive sequencing analysis of the small RNA fragmentome (RiboMarker)

open access: yesRNA
Circulating cell-free nucleic acids (cfDNA and cfRNA) found in blood and other biofluids are promising biomarkers for cancer. However, current methods exploiting tumor-derived cfDNA (ctDNA) are not sensitive enough in detecting minimal residual disease and early stages of cancer when it is more treatable.
Rachel C. Clark   +4 more
openaire   +3 more sources

Cancer treatment monitoring using cell-free DNA fragmentomes

open access: yesNature Communications
AbstractCirculating cell-free DNA (cfDNA) assays for monitoring individuals with cancer typically rely on prior identification of tumor-specific mutations. Here, we develop a tumor-independent and mutation-independent approach (DELFI-tumor fraction, DELFI-TF) using low-coverage whole genome sequencing to determine the cfDNA tumor fraction and validate ...
Iris van ’t Erve   +21 more
openaire   +4 more sources

Gastric cancer detection by stomach chromatin–anchored salivary cell-free DNA fragmentomics

open access: yes
The current liquid biopsy paradigm rests mostly on plasma cell-free DNA (cfDNA), and only to a limited extent on other biofluids. Saliva is molecularly rich but difficult to use, as tumour signal must be separated from abundant background noise. Salivary
M. Constanza Camargo   +29 more
core   +1 more source

Abstracts

open access: yesMolecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Fragmentation signatures in cancer patients resemble those of patients with vascular or autoimmune diseases

open access: yes
Multiple case-controlled studies have shown that analyzing fragmentation patterns in plasma cell-free DNA (cfDNA) can distinguish individuals with cancer from healthy controls.
Kinzler, KW   +31 more
core   +1 more source

A Pilot Study of Plasma Cell-Free DNA Fragmentomics in Gallbladder Cancer

open access: yesJHEP Reports
Gallbladder cancer (GBC) is a rare and highly lethal biliary tract cancer with limited treatment options and lack of diagnostic and prognostic noninvasive biomarkers. Circulating cell-free DNA (cfDNA) offers a noninvasive means to capture fragmentomics alterations that may assist with diagnosis and biological characterization. This pilot study aimed to
Michael, Daniels   +13 more
openaire   +2 more sources

Genome-wide cfDNA fragmentation patterns in cerebrospinal fluid reflect medulloblastoma groups

open access: yesnpj Precision Oncology
Identifying molecular groups in medulloblastoma currently requires invasive biopsies for accurate diagnosis. We analyzed cerebrospinal fluid cell-free DNA (cfDNA) fragmentation patterns in 122 samples as a minimally-invasive alternative.
Alexander L Markowitz   +6 more
doaj   +1 more source

Multidimensional cell-free DNA fragmentomics enables early detection of breast cancer

open access: yesBreast Cancer Research
Background Cell-free DNA (cfDNA) fragmentomics represents a transformative approach for early breast cancer detection, offering significant potential to improve patient survival through timely intervention.
Lixian Yang   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy